Skip to Main Content

life sciences

In the life sciences industry you’ll find companies researching, developing and manufacturing medicines and medical devices based on biotech advances and breakthroughs. Life science disciplines covered here include microbiology, biotechnology, genetics, molecular and cell biology, neuroscience, and biochemistry.

Latest

In the Lab Rohan Rajeev

Protein maps in cerebrospinal fluid offer insight into Alzheimer’s biology

The Readout LOUD Allison DeAngelis and Brittany Trang

Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

Don't Miss Sarah Mupo

The 42 best books and podcasts on health and science to check out this summer

In the Lab Jonathan Wosen

STAT Plus: Stephen Quake on the Chan Zuckerberg quest to cure, prevent, or manage all diseases by 2100

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout Elaine Chen

STAT Plus: Looking for signs of growth in Biogen’s earnings

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s big deal, biotech’s red numbers, & an industry history lesson

All Coverage

First Opinion James C. Robinson

The U.S. needs a bipartisan industrial policy for the life sciences

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

advertisement

Politics Sarah Owermohle

STAT Plus: Who can sue the FDA? Answering Justice Alito’s question from the mifepristone arguments

Politics Sarah Owermohle

STAT Plus: SCOTUS’ abortion pill mifepristone case is really about the FDA

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Live! From the STAT Breakthrough Summit East

Biotech Damian Garde

STAT Plus: Regeneron’s plot to ‘cure’ allergies

Politics John Wilkerson

STAT Plus: Medicare expected to negotiate obesity drug prices soon, new analysis predicts

Biotech Catherine Carlock — Boston Globe

STAT Plus: The Boston area built a ton of lab space. Now many of those buildings are opening empty

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

A dilemma in ALS, the first MASH drug, & why gene therapy is hard

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Politics Rachel Cohrs Zhang

STAT Plus: Pharma giants, government spar in court over Medicare drug price negotiation

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

VC turmoil, GLP-1 competition, & the war on recovery

Politics Rachel Cohrs Zhang

STAT Plus: Biden to propose expanding Medicare drug price negotiation in State of the Union

Politics John Wilkerson

STAT Plus: Republicans consider a new attack on Biden ‘march-in’ plan for lower drug prices

Politics Rachel Cohrs Zhang

STAT Plus: White House touts incremental step in Medicare drug price negotiation: counteroffers

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

D.C. Diagnosis Rachel Cohrs Zhang

House looks to weaken Medicare negotiation

Pharmalot Rachel Cohrs Zhang and Ed Silverman

STAT Plus: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Humira’s legacy, CEO symbolism, and genomic surgery